Published in Oncotarget on November 10, 2015
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget (2016) 0.86
Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J (2016) 0.78
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett (2016) 0.78
Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One (2017) 0.75
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol (2012) 5.41
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg (2004) 3.50
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys (2014) 3.23
Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: results of a decision-analytic model. Dis Colon Rectum (2015) 2.67
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia (2003) 2.29
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol (2015) 2.12
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum (2010) 1.45
Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum (2013) 1.40
Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) (2008) 1.26
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut (2015) 1.17
Nonoperative approaches to rectal cancer: a critical evaluation. Semin Radiat Oncol (2011) 1.17
The consequences of structural genomic alterations in humans: genomic disorders, genomic instability and cancer. Semin Cell Dev Biol (2011) 1.17
Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis (2012) 1.01
Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer (2014) 1.00
The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol (2011) 0.99
ASPP2: a gene that controls life and death in vivo. Cell Cycle (2006) 0.86
ICRmax: an optimized approach to detect tumor-specific interchromosomal rearrangements for clinical application. Genomics (2015) 0.79